ASCO Preview: Multiple Chinese Biotechs Showcase NSCLC Assets
More Positive Data For Toripalimab
Chinese biotechs Biokin, Dizal, Junshi and Kelun Biotech are presenting four of the most closely-followed oral reports at ASCO on new clinical results for their candidates for non-small cell lung cancer.